Rhinovirus Infection in AsthmaNCT01159782
Mechanisms of Rhinovirus Induced Asthma Exacerbations
A study testing Rhinovirus infection in people with Rhinovirus Infection in Asthma, run by Imperial College London at 1 site in United Kingdom.
Trial summary
We, the investigators, hypothesise that there are distinct gene profiles in rhinovirus-induced acute exacerbations of asthma. We further hypothesise that these changes in gene expression involve both known mediators of the asthma phenotype as well as other molecules not previously associated with asthma. Read more about this study
- Who is it for?
- Ages 18 to 55 yearsHealthy volunteers can take part
- Conditions the study is for
- Rhinovirus Infection in Asthma
- What is being tested?
- Rhinovirus infection
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 46 participants
- Where
- 1 siteUnited Kingdom
- Study dates
- 12 Oct 2011to 30 Apr 2014
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 55 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Age 18-55 years Doctor diagnosis of asthma Histamine PC20 < 8 mg/mL Mild-to-moderate disease based on 2004 GINA criteria Treatment with either short-acting β-agonists (SABA) alone or with maintenance inhaled corticosteroids (daily dose between 200 μg and 1000 μg BDP equivalent) Worsening asthma symptoms with infection since last change in asthma therapy Atopic on skin testing (≥ 1 positive skin prick test on a panel of 10 aeroallergens)
- Age 18-55 years No history or clinical diagnosis of asthma or any other significant respiratory disease No history of allergic rhinitis or eczema Negative responses on skin prick testing (PC)20 > 8 µg/mL Absence of significant systemic disease
Who cannot join
- History of severe asthma defined by GINA Smoking history over past 6 months or > 5 pack year history Current symptoms of allergic rhinitis Current or previous history of significant respiratory disease (other than asthma) Any clinically relevant abnormality on screening or detected significant systemic disease Asthma exacerbation or viral illness within the previous 6 weeks Treatment with oral corticosteroids in the previous 3 months Current use of any nasal medication, anti-histamine, anti-leukotrienes, LABA, or anti-IgE therapy Presence of serum neutralising antibodies to rhinovirus-16 at screening Pregnant or breastfeeding women Contact with infants or elderly at home or at work
- History of atopy, asthma or any significant respiratory disease Smoking history over past 6 months or > 5 pack year history Current symptoms of rhinitis Any clinically relevant abnormality on screening or detected significant systemic disease Viral illness within the previous 6 weeks Current use of any nasal medication or anti-histamine Presence of serum neutralising antibodies to rhinovirus-16 at screening Pregnant or breastfeeding women Contact with infants or elderly at home or at work
Trial locations and contacts
1 site in 1 country.
United Kingdom1 site
National Heart and Lung Institute
London, England, W2 1PG
About this study
Official title: Human Model of Rhinovirus Induced Acute Asthma Exacerbations
We, the investigators, hypothesise that there are distinct gene profiles in rhinovirus-induced acute exacerbations of asthma. We further hypothesise that these changes in gene expression involve both known mediators of the asthma phenotype as well as other molecules not previously associated with asthma.
The primary objective of this study is to use gene array analysis to determine differentially expressed genes in bronchial epithelial cells and alveolar macrophages from normal and asthmatic subjects before and during rhinovirus infection in vivo. A secondary objective is to determine whether any altered expressions are related to symptom severity, virus load, lung function or airway inflammation in vivo.
Read more
We plan to recruit 45 subjects: 15 healthy volunteers, 15 asthmatics naïve to inhaled corticosteroid therapy, and 15 asthmatics on inhaled corticosteroids who will undergo two bronchoscopies, one prior to infection with rhinovirus and the second 4 days post inoculation. Bronchial brushings, biopsies and bronchoalveolar lavage (BAL) will be performed. RNA will be extracted with TRIzol reagent (Invitrogen, Carlsbad, CA) and purified by passage through RNeasy columns (Qiagen, Valencia, CA). Exon 1.0ST array chips (Affymetrix, Santa Clara, CA) will be used to analyse changes in gene expression. These are the most powerful genome expression tools available with 1.4 million probe sets and over 5.5 million features per array. Genes found to be significantly upregulated will be confirmed by quantitative RT-PCR.
Using a novel method of collecting undiluted bronchial epithelial lining fluid (bronchosorption) large numbers of proteins will be measured with a MesoScale Discovery multiplexed array system (MesoScale Discovery, Gaithersburg, Md) allowing further confirmation of the gene array results as well as providing in vivo evidence of dysregulated protein production in asthmatics. Gene expression and protein levels will be correlated with viral load, symptom scores, lung function and airway inflammation in vivo.
This study represents the first comprehensive evaluation of changes in bronchial epithelial gene expression during rhinovirus infection in vivo and therefore has the potential to provide significant insights into the host response in asthma and identify potential novel targets for further evaluation.
- Conditions
- Rhinovirus Infection in Asthma
- Being tested
- Rhinovirus infection
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Rhinovirus infectionOther
All subjects (asthmatic and non asthmatic healthy)will be infected with Rhinovirus 16.
| Study group | Role | What they receive |
|---|---|---|
| Asthma, Healthy | Other | Asthmatics or Healthy Volunteers Receives: Other: Rhinovirus infection |
What is being measured
The primary outcome is the main question the study is designed to answer.
Differentially expressed genes in bronchial epithelial cells and alveolar macrophages from normal and asthmatic subjects before and during rhinovirus infection
Measured: april 2012
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Jul 2010 (estimated)
- Study start12 Oct 2011
- Primary completion30 Apr 2014
- Study completion30 Apr 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (16)Papers the sponsor has linked to this study.
- Other trials for Rhinovirus Infection in AsthmaStudies of the same condition, open and under way.
- More trials run by Imperial College LondonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 46 participants (actual)
Sponsor and investigators
- Lead sponsor
- Imperial College London
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01159782
- Sponsor's protocol ID
- 09/H0712/59
- Status last verified
- Mar 2025
- First submitted
- 8 Jul 2010
- Last updated
- 6 Mar 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Jackson DJ, Makrinioti H, Rana BM, Shamji BW, Trujillo-Torralbo MB, Footitt J, Jerico Del-Rosario, Telcian AG, Nikonova A, Zhu J, Aniscenko J, Gogsadze L, Bakhsoliani E, Traub S, Dhariwal J, Porter J, Hunt D, Hunt T, Hunt T, Stanciu LA, Khaitov M, Bartlett NW, Edwards MR, Kon OM, Mallia P, Papadopoulos NG, Akdis CA, Westwick J, Edwards MJ, Cousins DJ, Walton RP, Johnston SL. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med. 2014 Dec 15;190(12):1373-82. doi: 10.1164/rccm.201406-1039OC.
PubMed 25350863Messaoud-Nacer Y, Culerier E, Rose S, Maillet I, Boussad R, Veront C, Savigny F, Malissen B, Radzikowska U, Sokolowska M, da Silva GVL, Edwards MR, Jackson DJ, Johnston SL, Ryffel B, Quesniaux VF, Togbe D. STING-dependent induction of neutrophilic asthma exacerbation in response to house dust mite. Allergy. 2025 Mar;80(3):715-737. doi: 10.1111/all.16369. Epub 2024 Oct 28.
PubMed 39466641Curren B, Ahmed T, Howard DR, Ashik Ullah M, Sebina I, Rashid RB, Al Amin Sikder M, Namubiru P, Bissell A, Ngo S, Jackson DJ, Toussaint M, Edwards MR, Johnston SL, McSorley HJ, Phipps S. IL-33-induced neutrophilic inflammation and NETosis underlie rhinovirus-triggered exacerbations of asthma. Mucosal Immunol. 2023 Oct;16(5):671-684. doi: 10.1016/j.mucimm.2023.07.002. Epub 2023 Aug 15.
PubMed 37506849Radzikowska U, Eljaszewicz A, Tan G, Stocker N, Heider A, Westermann P, Steiner S, Dreher A, Wawrzyniak P, Ruckert B, Rodriguez-Coira J, Zhakparov D, Huang M, Jakiela B, Sanak M, Moniuszko M, O'Mahony L, Jutel M, Kebadze T, Jackson DJ, Edwards MR, Thiel V, Johnston SL, Akdis CA, Sokolowska M. Rhinovirus-induced epithelial RIG-I inflammasome suppresses antiviral immunity and promotes inflammation in asthma and COVID-19. Nat Commun. 2023 Apr 22;14(1):2329. doi: 10.1038/s41467-023-37470-4.
PubMed 37087523Farne H, Lin L, Jackson DJ, Rattray M, Simpson A, Custovic A, Joshi S, Wilson PA, Williamson R, Edwards MR, Singanayagam A, Johnston SL. In vivo bronchial epithelial interferon responses are augmented in asthma on day 4 following experimental rhinovirus infection. Thorax. 2022 Sep;77(9):929-932. doi: 10.1136/thoraxjnl-2021-217389. Epub 2022 Jul 5.
PubMed 35790388Williams TC, Jackson DJ, Maltby S, Walton RP, Ching YM, Glanville N, Singanayagam A, Brewins JJ, Clarke D, Hirsman AG, Loo SL, Wei L, Beale JE, Casolari P, Caramori G, Papi A, Belvisi M, Wark PAB, Johnston SL, Edwards MR, Bartlett NW. Rhinovirus-induced CCL17 and CCL22 in Asthma Exacerbations and Differential Regulation by STAT6. Am J Respir Cell Mol Biol. 2021 Mar;64(3):344-356. doi: 10.1165/rcmb.2020-0011OC.
PubMed 33264064Nikonova A, Khaitov M, Jackson DJ, Traub S, Trujillo-Torralbo MB, Kudlay DA, Dvornikov AS, Del-Rosario A, Valenta R, Stanciu LA, Khaitov R, Johnston SL. M1-like macrophages are potent producers of anti-viral interferons and M1-associated marker-positive lung macrophages are decreased during rhinovirus-induced asthma exacerbations. EBioMedicine. 2020 Apr;54:102734. doi: 10.1016/j.ebiom.2020.102734. Epub 2020 Apr 9.
PubMed 32279057Upton N, Jackson DJ, Nikonova AA, Hingley-Wilson S, Khaitov M, Del Rosario A, Traub S, Trujillo-Torralbo MB, Habibi M, Elkin SL, Kon OM, Edwards MR, Mallia P, Footitt J, Macintyre J, Stanciu LA, Johnston SL, Sykes A. Rhinovirus induction of fractalkine (CX3CL1) in airway and peripheral blood mononuclear cells in asthma. PLoS One. 2017 Aug 31;12(8):e0183864. doi: 10.1371/journal.pone.0183864. eCollection 2017.
PubMed 28859129Toussaint M, Jackson DJ, Swieboda D, Guedan A, Tsourouktsoglou TD, Ching YM, Radermecker C, Makrinioti H, Aniscenko J, Bartlett NW, Edwards MR, Solari R, Farnir F, Papayannopoulos V, Bureau F, Marichal T, Johnston SL. Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation. Nat Med. 2017 Jun;23(6):681-691. doi: 10.1038/nm.4332. Epub 2017 May 1.
PubMed 28459437Hansel TT, Tunstall T, Trujillo-Torralbo MB, Shamji B, Del-Rosario A, Dhariwal J, Kirk PDW, Stumpf MPH, Koopmann J, Telcian A, Aniscenko J, Gogsadze L, Bakhsoliani E, Stanciu L, Bartlett N, Edwards M, Walton R, Mallia P, Hunt TM, Hunt TL, Hunt DG, Westwick J, Edwards M, Kon OM, Jackson DJ, Johnston SL. A Comprehensive Evaluation of Nasal and Bronchial Cytokines and Chemokines Following Experimental Rhinovirus Infection in Allergic Asthma: Increased Interferons (IFN-gamma and IFN-lambda) and Type 2 Inflammation (IL-5 and IL-13). EBioMedicine. 2017 May;19:128-138. doi: 10.1016/j.ebiom.2017.03.033. Epub 2017 Mar 28.
PubMed 28373098Naveed SU, Clements D, Jackson DJ, Philp C, Billington CK, Soomro I, Reynolds C, Harrison TW, Johnston SL, Shaw DE, Johnson SR. Matrix Metalloproteinase-1 Activation Contributes to Airway Smooth Muscle Growth and Asthma Severity. Am J Respir Crit Care Med. 2017 Apr 15;195(8):1000-1009. doi: 10.1164/rccm.201604-0822OC.
PubMed 27967204Niespodziana K, Cabauatan CR, Jackson DJ, Gallerano D, Trujillo-Torralbo B, Del Rosario A, Mallia P, Valenta R, Johnston SL. Rhinovirus-induced VP1-specific Antibodies are Group-specific and Associated With Severity of Respiratory Symptoms. EBioMedicine. 2014 Nov 18;2(1):64-70. doi: 10.1016/j.ebiom.2014.11.012. eCollection 2015 Jan.
PubMed 26137535Jackson DJ, Trujillo-Torralbo MB, del-Rosario J, Bartlett NW, Edwards MR, Mallia P, Walton RP, Johnston SL. The influence of asthma control on the severity of virus-induced asthma exacerbations. J Allergy Clin Immunol. 2015 Aug;136(2):497-500.e3. doi: 10.1016/j.jaci.2015.01.028. Epub 2015 Mar 13. No abstract available.
PubMed 25772596Jackson DJ, Glanville N, Trujillo-Torralbo MB, Shamji BW, Del-Rosario J, Mallia P, Edwards MJ, Walton RP, Edwards MR, Johnston SL. Interleukin-18 is associated with protection against rhinovirus-induced colds and asthma exacerbations. Clin Infect Dis. 2015 May 15;60(10):1528-31. doi: 10.1093/cid/civ062. Epub 2015 Feb 2.
PubMed 25645216Beale J, Jayaraman A, Jackson DJ, Macintyre JDR, Edwards MR, Walton RP, Zhu J, Man Ching Y, Shamji B, Edwards M, Westwick J, Cousins DJ, Yi Hwang Y, McKenzie A, Johnston SL, Bartlett NW. Rhinovirus-induced IL-25 in asthma exacerbation drives type 2 immunity and allergic pulmonary inflammation. Sci Transl Med. 2014 Oct 1;6(256):256ra134. doi: 10.1126/scitranslmed.3009124.
PubMed 25273095
Study at a glance
From the registry record, last updated by the sponsor on 6 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Human Model of Rhinovirus Induced Acute Asthma Exacerbations
- ClinicalTrials.gov ID
- NCT01159782
- Acronym / sponsor ID
- 09/H0712/59
- Conditions
- Rhinovirus Infection in Asthma
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 46 participants (actual)
- Lead sponsor
- Imperial College LondonUniversity, hospital or other
- Study start
- 12 Oct 2011 (actual)
- Primary completion
- 30 Apr 2014 (actual)
- Study completion
- 30 Apr 2014 (actual)
- First posted
- 9 Jul 2010 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
We, the investigators, hypothesise that there are distinct gene profiles in rhinovirus-induced acute exacerbations of asthma. We further hypothesise that these changes in gene expression involve both known mediators of the asthma phenotype as well as other molecules not previously associated with asthma.
The primary objective of this study is to use gene array analysis to determine differentially expressed genes in bronchial epithelial cells and alveolar macrophages from normal and asthmatic subjects before and during rhinovirus infection in vivo. A secondary objective is to determine whether any altered expressions are related to symptom severity, virus load, lung function or airway inflammation in vivo.
We plan to recruit 45 subjects: 15 healthy volunteers, 15 asthmatics naïve to inhaled corticosteroid therapy, and 15 asthmatics on inhaled corticosteroids who will undergo two bronchoscopies, one prior to infection with rhinovirus and the second 4 days post inoculation. Bronchial brushings, biopsies and bronchoalveolar lavage (BAL) will be performed. RNA will be extracted with TRIzol reagent (Invitrogen, Carlsbad, CA) and purified by passage through RNeasy columns (Qiagen, Valencia, CA). Exon 1.0ST array chips (Affymetrix, Santa Clara, CA) will be used to analyse changes in gene expression. These are the most powerful genome expression tools available with 1.4 million probe sets and over 5.5 million features per array. Genes found to be significantly upregulated will be confirmed by quantitative RT-PCR.
Using a novel method of collecting undiluted bronchial epithelial lining fluid (bronchosorption) large numbers of proteins will be measured with a MesoScale Discovery multiplexed array system (MesoScale Discovery, Gaithersburg, Md) allowing further confirmation of the gene array results as well as providing in vivo evidence of dysregulated protein production in asthmatics. Gene expression and protein levels will be correlated with viral load, symptom scores, lung function and airway inflammation in vivo.
This study represents the first comprehensive evaluation of changes in bronchial epithelial gene expression during rhinovirus infection in vivo and therefore has the potential to provide significant insights into the host response in asthma and identify potential novel targets for further evaluation.
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Asthma, Healthy | Other | Other: Rhinovirus infectionAsthmatics or Healthy Volunteers |
Who may qualify
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Age 18-55 years Doctor diagnosis of asthma Histamine PC20 < 8 mg/mL Mild-to-moderate disease based on 2004 GINA criteria Treatment with either short-acting β-agonists (SABA) alone or with maintenance inhaled corticosteroids (daily dose between 200 μg and 1000 μg BDP equivalent) Worsening asthma symptoms with infection since last change in asthma therapy Atopic on skin testing (≥ 1 positive skin prick test on a panel of 10 aeroallergens)
- Age 18-55 years No history or clinical diagnosis of asthma or any other significant respiratory disease No history of allergic rhinitis or eczema Negative responses on skin prick testing (PC)20 > 8 µg/mL Absence of significant systemic disease
Key exclusion criteria (2 listed)
- History of severe asthma defined by GINA Smoking history over past 6 months or > 5 pack year history Current symptoms of allergic rhinitis Current or previous history of significant respiratory disease (other than asthma) Any clinically relevant abnormality on screening or detected significant systemic disease Asthma exacerbation or viral illness within the previous 6 weeks Treatment with oral corticosteroids in the previous 3 months Current use of any nasal medication, anti-histamine, anti-leukotrienes, LABA, or anti-IgE therapy Presence of serum neutralising antibodies to rhinovirus-16 at screening Pregnant or breastfeeding women Contact with infants or elderly at home or at work
- History of atopy, asthma or any significant respiratory disease Smoking history over past 6 months or > 5 pack year history Current symptoms of rhinitis Any clinically relevant abnormality on screening or detected significant systemic disease Viral illness within the previous 6 weeks Current use of any nasal medication or anti-histamine Presence of serum neutralising antibodies to rhinovirus-16 at screening Pregnant or breastfeeding women Contact with infants or elderly at home or at work
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Rhinovirus infectionAll subjects (asthmatic and non asthmatic healthy)will be infected with Rhinovirus 16. | Other | Asthma, Healthy |
Primary outcome
Differentially expressed genes in bronchial epithelial cells and alveolar macrophages from normal and asthmatic subjects before and during rhinovirus infection
Time frame: april 2012
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 Mar 2025.
- Results publication: PubMed 25350863Jackson DJ, Makrinioti H, Rana BM, Shamji BW, Trujillo-Torralbo MB, Footitt J, Jerico Del-Rosario, Telcian AG, Nikonova A, Zhu J, Aniscenko J, Gogsadze L, Bakhsoliani E, Traub S, Dhariwal J, Porter J, Hunt D, Hunt T, Hunt T, Stanciu LA, Khaitov M, Bartlett NW, Edwards MR, Kon OM, Mallia P, Papadopoulos NG, Akdis CA, Westwick J, Edwards MJ, Cousins DJ, Walton RP, Johnston SL. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med. 2014 Dec 15;190(12):1373-82. doi: 10.1164/rccm.201406-1039OC.
- Results publication: PubMed 39466641Messaoud-Nacer Y, Culerier E, Rose S, Maillet I, Boussad R, Veront C, Savigny F, Malissen B, Radzikowska U, Sokolowska M, da Silva GVL, Edwards MR, Jackson DJ, Johnston SL, Ryffel B, Quesniaux VF, Togbe D. STING-dependent induction of neutrophilic asthma exacerbation in response to house dust mite. Allergy. 2025 Mar;80(3):715-737. doi: 10.1111/all.16369. Epub 2024 Oct 28.
- Results publication: PubMed 37506849Curren B, Ahmed T, Howard DR, Ashik Ullah M, Sebina I, Rashid RB, Al Amin Sikder M, Namubiru P, Bissell A, Ngo S, Jackson DJ, Toussaint M, Edwards MR, Johnston SL, McSorley HJ, Phipps S. IL-33-induced neutrophilic inflammation and NETosis underlie rhinovirus-triggered exacerbations of asthma. Mucosal Immunol. 2023 Oct;16(5):671-684. doi: 10.1016/j.mucimm.2023.07.002. Epub 2023 Aug 15.
- Results publication: PubMed 37087523Radzikowska U, Eljaszewicz A, Tan G, Stocker N, Heider A, Westermann P, Steiner S, Dreher A, Wawrzyniak P, Ruckert B, Rodriguez-Coira J, Zhakparov D, Huang M, Jakiela B, Sanak M, Moniuszko M, O'Mahony L, Jutel M, Kebadze T, Jackson DJ, Edwards MR, Thiel V, Johnston SL, Akdis CA, Sokolowska M. Rhinovirus-induced epithelial RIG-I inflammasome suppresses antiviral immunity and promotes inflammation in asthma and COVID-19. Nat Commun. 2023 Apr 22;14(1):2329. doi: 10.1038/s41467-023-37470-4.
- Results publication: PubMed 35790388Farne H, Lin L, Jackson DJ, Rattray M, Simpson A, Custovic A, Joshi S, Wilson PA, Williamson R, Edwards MR, Singanayagam A, Johnston SL. In vivo bronchial epithelial interferon responses are augmented in asthma on day 4 following experimental rhinovirus infection. Thorax. 2022 Sep;77(9):929-932. doi: 10.1136/thoraxjnl-2021-217389. Epub 2022 Jul 5.
- Results publication: PubMed 33264064Williams TC, Jackson DJ, Maltby S, Walton RP, Ching YM, Glanville N, Singanayagam A, Brewins JJ, Clarke D, Hirsman AG, Loo SL, Wei L, Beale JE, Casolari P, Caramori G, Papi A, Belvisi M, Wark PAB, Johnston SL, Edwards MR, Bartlett NW. Rhinovirus-induced CCL17 and CCL22 in Asthma Exacerbations and Differential Regulation by STAT6. Am J Respir Cell Mol Biol. 2021 Mar;64(3):344-356. doi: 10.1165/rcmb.2020-0011OC.
- Results publication: PubMed 32279057Nikonova A, Khaitov M, Jackson DJ, Traub S, Trujillo-Torralbo MB, Kudlay DA, Dvornikov AS, Del-Rosario A, Valenta R, Stanciu LA, Khaitov R, Johnston SL. M1-like macrophages are potent producers of anti-viral interferons and M1-associated marker-positive lung macrophages are decreased during rhinovirus-induced asthma exacerbations. EBioMedicine. 2020 Apr;54:102734. doi: 10.1016/j.ebiom.2020.102734. Epub 2020 Apr 9.
- Results publication: PubMed 28859129Upton N, Jackson DJ, Nikonova AA, Hingley-Wilson S, Khaitov M, Del Rosario A, Traub S, Trujillo-Torralbo MB, Habibi M, Elkin SL, Kon OM, Edwards MR, Mallia P, Footitt J, Macintyre J, Stanciu LA, Johnston SL, Sykes A. Rhinovirus induction of fractalkine (CX3CL1) in airway and peripheral blood mononuclear cells in asthma. PLoS One. 2017 Aug 31;12(8):e0183864. doi: 10.1371/journal.pone.0183864. eCollection 2017.
- Results publication: PubMed 28459437Toussaint M, Jackson DJ, Swieboda D, Guedan A, Tsourouktsoglou TD, Ching YM, Radermecker C, Makrinioti H, Aniscenko J, Bartlett NW, Edwards MR, Solari R, Farnir F, Papayannopoulos V, Bureau F, Marichal T, Johnston SL. Host DNA released by NETosis promotes rhinovirus-induced type-2 allergic asthma exacerbation. Nat Med. 2017 Jun;23(6):681-691. doi: 10.1038/nm.4332. Epub 2017 May 1.
- Results publication: PubMed 28373098Hansel TT, Tunstall T, Trujillo-Torralbo MB, Shamji B, Del-Rosario A, Dhariwal J, Kirk PDW, Stumpf MPH, Koopmann J, Telcian A, Aniscenko J, Gogsadze L, Bakhsoliani E, Stanciu L, Bartlett N, Edwards M, Walton R, Mallia P, Hunt TM, Hunt TL, Hunt DG, Westwick J, Edwards M, Kon OM, Jackson DJ, Johnston SL. A Comprehensive Evaluation of Nasal and Bronchial Cytokines and Chemokines Following Experimental Rhinovirus Infection in Allergic Asthma: Increased Interferons (IFN-gamma and IFN-lambda) and Type 2 Inflammation (IL-5 and IL-13). EBioMedicine. 2017 May;19:128-138. doi: 10.1016/j.ebiom.2017.03.033. Epub 2017 Mar 28.
- Results publication: PubMed 27967204Naveed SU, Clements D, Jackson DJ, Philp C, Billington CK, Soomro I, Reynolds C, Harrison TW, Johnston SL, Shaw DE, Johnson SR. Matrix Metalloproteinase-1 Activation Contributes to Airway Smooth Muscle Growth and Asthma Severity. Am J Respir Crit Care Med. 2017 Apr 15;195(8):1000-1009. doi: 10.1164/rccm.201604-0822OC.
- Results publication: PubMed 26137535Niespodziana K, Cabauatan CR, Jackson DJ, Gallerano D, Trujillo-Torralbo B, Del Rosario A, Mallia P, Valenta R, Johnston SL. Rhinovirus-induced VP1-specific Antibodies are Group-specific and Associated With Severity of Respiratory Symptoms. EBioMedicine. 2014 Nov 18;2(1):64-70. doi: 10.1016/j.ebiom.2014.11.012. eCollection 2015 Jan.
Related trials for Rhinovirus Infection in Asthma
RecruitingPhase 1/2
RIG 101 Trial in Healthy Adults and Adults With Asthma
Healthy Adult Participants, Asthma Exacerbation
RecruitingPhase 4
Innovative Steroid Treatment to Reduce Asthma Development in Children After First-time Rhinovirus Induced Wheezing
Asthma, Inflammation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Rhinovirus infection in people with Rhinovirus Infection in Asthma, run by Imperial College London at 1 site in United Kingdom.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 6 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Differentially expressed genes in bronchial epithelial cells and alveolar macrophages from normal and asthmatic subjects before and during rhinovirus infection (time frame: april 2012). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT01159782, which also lists 16 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 Mar 2025.